Just came across the same PR but you beat me to it. Nice catch on the PR not identifying the MOA as being the same as Retraglutide. I would be GLP1 + GIP are likely. Third agonist could be something new or a Amylin or a Calcitonin Agonists.
I wonder if VKTX will become the first to have a Quad agonist in the clinic. (GLP1,GIP, Amylin and Calcitonin anyone?) Even more curious on what acronym they could come up with.
Market Data 
Markets 
AI
